1University of Houston, College of Optometry, Boulder, Colorado
2Johnson & Johnson Visioncare, Inc., Jacksonville, Florida *[email protected]
Submitted: January 7, 2019
Accepted: February 28, 2019
Funding/Support: None of the authors have reported funding/support.
Conflict of Interest Disclosure: MAB is a consultant for a number of companies including Acucela (Seattle, WA); Apellis Pharmaceuticals, Inc. (Crestwood, KY); Alcon Laboratories, Inc. (Fort Worth, TX); Carl Zeiss Meditec AG (Dublin, CA); CooperVision, Inc. (Victor, NY); Essilor of America (Lewisville, TX); Eyenovia, Inc. (New York, NY); Genentech, Inc. (San Francisco, CA); Innovega, Inc. (Seattle, WA); jCyte, Inc. (Newport, CA); Johnson & Johnson Visioncare, Inc. (Jacksonville, FL); Novartis Pharma AG (Basel, Switzerland); and Tear Film Innovations (San Diego, CA). NAB is an employee of Johnson & Johnson Visioncare, Inc.
Author Contributions and Acknowledgments: Conceptualization & Writing: MAB; Writing – Review & Editing: NAB.
The ideas expressed here have been enhanced by discussions with Paul Chamberlain (Cooper Vision, Inc.).